Revenue growing at 57% year-over-year with a combined growth-plus-profitability metric of 57 signals efficient scaling, and technical indicators show broad-based strength across moving averages, MACD, and on-balance volume — yet free cash flow is negative, business quality falls below the minimum acceptable threshold, and the share price already trades above the analyst-derived price target, leaving a negative reward-to-risk setup at current levels.
Thesis pillars
- Exceptional Revenue Growth Rule Of 40→Stable
- Technical Uptrend Broad Accumulation→Stable
- Cash Burning Quality Below Minimum→Stable
- +1 more pillar — see the Why tab for full reasoning
Axsome Therapeutics, Inc. (AXSM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $243.00: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Elevated put/call ratio: 4.76; Below-average business quality; Rich valuation.
Axsome Therapeutics markets three FDA-approved CNS medicines in the U.S. — AUVELITY for MDD (approved August 2022), SUNOSI for excessive daytime sleepiness (acquired 2022), and SYMBRAVO for acute migraine (approved January 2025) — which together generated $638.5 million in... Read more
Sell if holding. Engine safety override at $243.00: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Elevated put/call ratio: 4.76; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About Axsome Therapeutics, Inc.
About Axsome Therapeutics, Inc.
Axsome Therapeutics generated $638.5 million in combined revenue from three FDA-approved CNS products in 2025, representing 66% growth year-over-year: AUVELITY (approved August 2022 for major depressive disorder), SUNOSI (acquired 2022 for excessive daytime sleepiness in patients with obstructive sleep apnea or narcolepsy), and SYMBRAVO (approved January 2025 for acute migraine). The lead pipeline asset, AXS-05, received Priority Review designation from the FDA in December 2025 for Alzheimer's disease agitation, with a PDUFA target action date of April 30, 2026.
Axsome commercializes all three approved products directly in the United States through a focused sales and marketing organization, targeting approximately 21 million U.S. MDD patients, 22 million adults with obstructive sleep apnea or narcolepsy, and 39 million adults experiencing migraine. SUNOSI's ex-U.S. rights outside 12 Asian markets — retained by originator SK Biopharmaceuticals — are licensed to Pharmanovia under a 2023 agreement covering Europe and parts of the Middle East and North Africa. Manufacturing is outsourced to third-party contract manufacturers under non-exclusive commercial supply agreements with no material contractual obligations beyond ordered supply. The company carries a credit facility with Blackstone Alternative Credit Advisors providing up to $570.0 million in term and revolving credit — closed May 8, 2025, bearing interest at SOFR plus 4.75% and maturing May 8, 2030.
Show full overview
The primary near-term binary risk is the FDA decision on AXS-05 for Alzheimer's disease agitation. The FDA granted Priority Review and Breakthrough Therapy designation for this indication. Across four Phase 3 trials, three met their primary endpoint and one did not, providing mixed but largely positive efficacy data. If the FDA declines approval, the commercial trajectory of the company's self-described lead product candidate could be materially disrupted. A parallel setback illustrates pipeline-wide regulatory exposure: the AXS-14 fibromyalgia NDA received a Refusal to File letter in 2025 because one pivotal trial used an endpoint structure the FDA deemed inadequate, with the FORWARD Phase 3 trial now underway to address the deficiency.
See also: Healthcare · Biotechnology
From Axsome Therapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — Axsome Therapeutics, Inc.
Latest news
- NEWS Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adol — benzinga Jun 26, 2026 positive
- NEWS TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300 — benzinga Jun 17, 2026 positive
- NEWS Axsome to Present New Sleep Disorder Data at SLEEP 2026, To Highlight AXS-12 and Solriamfetol Data for Narcolepsy and OS — benzinga Jun 15, 2026 positive
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga Jun 5, 2026 neutral
- NEWS Axsome Therapeutics Presents New SYMBRAVO Data At AHS 68th Annual Scientific Meeting — benzinga Jun 4, 2026 positive
Generated 2026-07-06T06:00:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineAXS-05 for Alzheimer's disease agitation10-K Item 1: 'Our lead product candidate, AXS-05 (dextromethorphan and bupropion), is currently being developed for the treatment of Alzheimer's disease (AD) agitation'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $243.00: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Elevated put/call ratio: 4.76; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $227.49. Score 5.0/10, moderate confidence.
Take-profit target: $248.82 (+1.8% upside). Prior stop was $227.49. Stop-loss: $227.49.
Target reached (1.8% upside); Quality below floor (3.8 < 4.0).
Axsome Therapeutics, Inc. trades at a P/E of N/A (forward 41.4). TrendMatrix value score: 3.5/10. Verdict: Sell.
27 analysts cover AXSM with a consensus score of 4.3/5. Average price target: $276.
What does Axsome Therapeutics, Inc. do?Axsome Therapeutics markets three FDA-approved CNS medicines in the U.S. — AUVELITY for MDD (approved August 2022),...
Axsome Therapeutics markets three FDA-approved CNS medicines in the U.S. — AUVELITY for MDD (approved August 2022), SUNOSI for excessive daytime sleepiness (acquired 2022), and SYMBRAVO for acute migraine (approved January 2025) — which together generated $638.5 million in revenue for 2025, representing 66% annual growth. The pipeline is anchored by AXS-05 for Alzheimer's disease agitation, with Priority Review designation and a PDUFA target date of April 30, 2026.